Anticonvulsants and suicide attempts in bipolar I disorders

Acta Psychiatrica Scandinavica

Volumn 135, Issue 5, 2017, Pages 470-478

  Bellivier, F ^a,b,c,d   Belzeaux, R ^d,e   Scott, J ^f,g   Courtet, P ^d,h,i   Golmard, J L ^j   Azorin, J M ^d,e  

^a INSERM   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d FONDATION FONDAMENTAL   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^f NEWCASTLE UNIVERSITY   (United Kingdom)

^g KING'S COLLEGE LONDON   (United Kingdom)

^h INSERM U1061   (France)

ⁱ LAPEYRONIE HOSPITAL   (France)

^j SORBONNE UNIVERSITÉ   (France)

more..

Author keywords

anticonvulsants; bipolar disorder; mania; mixed states; prospective study; suicide attempts

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; LITHIUM; NEUROLEPTIC AGENT;

ADULT; ALCOHOLISM; ARTICLE; BIPOLAR I DISORDER; BIPOLAR MANIA; DRUG DEPENDENCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RAPID CYCLING BIPOLAR DISORDER; RISK ASSESSMENT; SUICIDE ATTEMPT; BIPOLAR DISORDER; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; POISSON DISTRIBUTION; PSYCHOLOGY; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

ADULT; ANTICONVULSANTS; BIPOLAR DISORDER; FEMALE; HUMANS; MALE; MIDDLE AGED; POISSON DISTRIBUTION; PROSPECTIVE STUDIES; RISK FACTORS; SUICIDE, ATTEMPTED;

EID: 85011985648     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12709     Document Type: Article

References (48)

1. Angst J, Angst F, Gerber-Werder R, Gamma A. Suicide in 406 mood-disorder patients with and without long-term medication: a 40 to 44 years' follow-up. Arch Suicide Res 2005;9:279–300.
2. Dunner DL. Clinical consequences of under-recognized bipolar spectrum disorder. Bipolar Disord 2003;5:456–463.
3. Goodwin FK, Jamison KR. Manic-depressive illness. New York: Oxford University Press, 2007.
4. Schaffer A, Isometsa ET, Tondo L et al. International Society for Bipolar Disorders Task Force on Suicide: meta-analyses and meta-regression of correlates of suicide attempts and suicide deaths in bipolar disorder. Bipolar Disord 2015;17:1–16.
5. Rhimer Z. Prediction and prevention of suicide in bipolar disorders. Clin Neuropsychiatry 2005;2:48–54.
6. Tondo L, Isacsson G, Baldessarini R. Suicidal behaviour in bipolar disorder: risk and prevention. CNS Drugs 2003;17:491–511.
7. Baldessarini RJ, Tondo L, Davis P, Pompili M, Goodwin FK, Hennen J. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord 2006;8:625–639.
8. Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ 2013;346:f3646.
9. US Food and Drug Administration: FDA Alerts Health Care Providers to Risk of Suicidal Thoughts and Behaviour with Antiepileptic Medications. Jan 31, 2008. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm100200.htm
10. US Food and Drug Administration: Statistical Review and Evaluation: Antiepileptic Drugs and Suicidality. May 23, 2008. http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4372b1-01-FDA.pdf
11. Arana A, Wentworth CE, Ayuso-Mateos JL, Arellano FM. Suicide-related events in patients treated with antiepileptic drugs. N Engl J Med 2010;363:542–551.
12. Collins JC, McFarland BH. Divalproex, lithium and suicide among Medicaid patients with bipolar disorder. J Affect Disord 2008;107:23–28.
13. Gibbons RD, Hur K, Brown CH, Mann JJ. Relationship between antiepileptic drugs and suicide attempts in patients with bipolar disorder. Arch Gen Psychiatry 2009;66:1354–1360.
14. Patorno E, Bohn RL, Wahl PM et al. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA 2010;303:1401–1409.
15. Pugh MJ, Hesdorffer D, Wang CP et al. Temporal trends in new exposure to antiepileptic drug monotherapy and suicide-related behavior. Neurology 2013;81:1900–1906.
16. Smith EG, Austin KL, Kim HM et al. Suicide risk in Veterans Health Administration patients with mental health diagnoses initiating lithium or valproate: a historical prospective cohort study. BMC Psychiat 2014;14:357.
17. Yerevanian BI, Koek RJ, Mintz J. Bipolar pharmacotherapy and suicidal behavior. Part I: Lithium, divalproex and carbamazepine. J Affect Disord 2007;103:5–11.
18. Leon AC, Solomon DA, Li C et al. Antiepileptic drugs for bipolar disorder and the risk of suicidal behavior: a 30-year observational study. Am J Psychiatry 2012;169(3):285–291.
19. Oquendo MA, Galfalvy HC, Currier D et al. Treatment of suicide attempters with bipolar disorder: a randomized clinical trial comparing lithium and valproate in the prevention of suicidal behavior. Am J Psychiatry 2011;168:1050–1056. Erratum in: Am J Psychiatry 2012;169:223.
20. Friedman RA, Leon AC. Expanding the black box – depression, antidepressants, and the risk of suicide. N Engl J Med 2007;356:2343–2346.
21. Healy D. Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. Psychother Psychosom 2003;72:71–79.
22. Isacsson G, Holmgren P, Ahlner J. Selective serotonin reuptake inhibitor antidepressants and the risk of suicide: a controlled forensic database study of 14,857 suicides. Acta Psychiatr Scand 2005;111:286–290.
23. Cougnard A, Verdoux H, Grolleau A, Moride Y, Begaud B, Tournier M. Impact of antidepressants on the risk of suicide in patients with depression in real-life conditions: a decision analysis model. Psychol Medicine 2009;39:1307–1315.
24. Mcelroy SL, Kotwal R, Kaneria R, Keck PE Jr. Antidepressants and suicidal behavior in bipolar disorder. Bipolar Disord 2006;8:596–617.
25. Rissanen I, Jaaskelainen E, Isohanni M et al. Use of antipsychotic medication and suicidality–the Northern Finland Birth Cohort 1966. Hum Psychopharmacol 2012;27:476–485.
26. Goetz I, Tohen M, Reed C, Lorenzo M, Vieta E, Board EA. Functional impairment in patients with mania: baseline results of the EMBLEM study. Bipolar Disord 2007;9:45–52.
27. Haro JM, van Os J, Vieta E et al. Evidence for three distinct classes of ‘typical’, ‘psychotic’ and ‘dual’ mania: results from the EMBLEM study. Acta Psychiatr Scand 2006;113:112–120.
28. Vieta E, Panicali F, Goetz I et al. Olanzapine monotherapy and olanzapine combination therapy in the treatment of mania: 12-week results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) observational study. J Affect Disord 2008;106:63–72.
29. Cameron AC, Trivedi PK. Regression analysis of count data. 2nd ed. New York: Cambridge University Press; 2013.
30. Knudsen DC. Generalized Poisson regression: including a priori information using the method of offsets. Professional Geographer 1992;44:202–208.
31. Schaffer A, Isometsa ET, Azorin JM et al. A review of factors associated with greater likelihood of suicide attempts and suicide deaths in bipolar disorder: Part II of a report of the International Society for Bipolar Disorders Task Force on Suicide in Bipolar Disorder. Aust N Z J Psychiat 2015;49:1006–1020.
32. Cruz N, Vieta E, Comes M et al. Rapid-cycling bipolar I disorder: course and treatment outcome of a large sample across Europe. J Psychiatr Res 2008;42:1068–1075.
33. Paykel E, Abbott R, Morriss R, Hayhurst H, Scott J. Sub-syndromal and syndromal symptoms in the longitudinal course of bipolar disorder. British J Psychiat 2006;189:118–123.
34. Gunnell D, Hawton K, Ho D et al. Hospital admissions for self harm after discharge from psychiatric inpatient care: cohort study. BMJ 2008;337:a2278.
35. Mula M, Sander JW. Suicidal ideation in epilepsy and levetiracetam therapy. Epilepsy Behav 2007;11:130–132.
36. Nilsson L, Ahlbom A, Farahmand BY, Asberg M, Tomson T. Risk factors for suicide in epilepsy: a case control study. Epilepsia 2002;43:644–651.
37. Olesen JB, Hansen PR, Erdal J et al. Antiepileptic drugs and risk of suicide: a nationwide study. Pharmacoepidemiol Drug Saf 2010;19:518–524.
38. Gibbons RD, Hur K, Brown CH, Mann JJ. Antiepileptic drugs and suicide attempts in patients with bipolar disorder-reply. Arch Gen Psychiatr 2010;67:1326–1327.
39. Leverich GS, Altshuler LL, Frye MA et al. Factors associated with suicide attempts in 648 patients with bipolar disorder in the Stanley Foundation Bipolar Network. J Clin Psychiatry 2003;64:506–515.
40. Leverich GS, Post RM. Course of bipolar illness after history of childhood trauma. Lancet 2006;367:1040–1042.
41. Kim S, Choi KH, Baykiz AF, Gershenfeld HK. Suicide candidate genes associated with bipolar disorder and schizophrenia: an exploratory gene expression profiling analysis of post-mortem prefrontal cortex. BMC Genom 2007;8:413.
42. Marcus SR, Nadiger HA, Chandrakala MV, Rao TI, Sadasivudu B. Acute and short-term effects of lithium on glutamate metabolism in rat brain. Biochem Pharmacol 1986;35:365–369.
43. Collins RM Jr, Zielke HR, Woody RC. Valproate increases glutaminase and decreases glutamine synthetase activities in primary cultures of rat brain astrocytes. J Neurochem 1994;62:1137–1143.
44. Karege F, Perroud N, Burkhardt S et al. Alteration in kinase activity but not in protein levels of protein kinase B and glycogen synthase kinase-3beta in ventral prefrontal cortex of depressed suicide victims. Biol Psychiatry 2007;61:240–245.
45. Jin N, Kovács AD, Sui Z, Dewhurst S, Maggirwar SB. Opposite effects of lithium and valproic acid on trophic factor deprivation-induced glycogen synthase kinase-3 activation, c-Jun expression and neuronal cell death. Neuropharmacology 2005;48:576–583.
46. Beurel E, Jope RS. Inflammation and lithium: clues to mechanisms contributing to suicide-linked traits. Transl Psychiatry 2014;4:e488.
47. Dambach H, Hinkerohe D, Prochnow N et al. Glia and epilepsy: experimental investigation of antiepileptic drugs in an astroglia/microglia co-culture model of inflammation. Epilepsia 2014;55:184–192.
48. Kordes C, Sawitza I, Häussinger D. Canonical Wnt signaling maintains the quiescent stage of hepatic stellate cells. Biochem Biophys Res Commun 2008;367:116–123.